Related Content
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens launches high-impact push in support of World AIDS Day campaign
- FDA advisory committee recommends PrEP approval for Truvada
- Walgreens, Ebony encourage Americans to be 'Greater Than AIDS'
- AIDS Healthcare Foundation acquires MOMS Pharmacy
FOSTER CITY, Calif. — Drug maker Gilead Sciences has recalled a single lot of an injected drug used to treat an opportunistic infection in AIDS patients due to the presence of foreign matter in some vials, the company said.
Gilead announced the voluntary recall of lot B120217A of Vistide (cidofovir), an injected drug used to treat cytomegalovirus retinitis in patients with AIDS, due to particulate matter.
The company said that it had not received any complaints related to the problem, but that patients risked experiencing serious complications if injected with the particles. The lot was distributed in the United States, Canada and Europe to retail pharmacies, hospitals and wholesalers.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

